The authors investigated whether PCSK9 inhibition could represent a therapeutic strategy in calcific aortic valve stenosis (CAVS). A meta-analysis of 10 studies was performed to determine the impact of the PCSK9 R46L variant on CAVS, and the authors found that CAVS was less prevalent in carriers of this variant (odds ratio: 0.80 [95% confidence interval: 0.70 to 0.91]; p = 0.0011) compared with noncarriers. PCSK9 expression was higher in the aortic valves of patients CAVS compared with control patients. In human valve interstitials cells submitted to a pro-osteogenic medium, PCSK9 levels increased and a PCSK9 neutralizing antibody significantly reduced calcium accumulation.
Keywords: Ad DMEM, advanced Dulbecco’s modified Eagle’s medium; CAD, coronary artery disease; CAVS, calcific aortic valve stenosis; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); PBS, phosphate-buffered saline; PBST, 1× phosphate-buffered saline with 0.1% Triton; PCSK9, proprotein convertase subtilisin/kexin type 9; SNP, single nucleotide polymorphism; TC, total cholesterol; VIC, valve interstitial cell; VLDL-C, very-low-density lipoprotein cholesterol; aortic valve interstitial cell; apoB, apolipoprotein B; apolipoprotein B; calcific aortic valve stenosis; lipoprotein(a); proprotein convertase subtilisin/kexin type 9; wGRS, weighted genetic risk score.
© 2020 The Authors.